Did FDA Approve New Alzheimer’s Drug Just In Time For Biden 2024 Re-Election Campaign?

(Congress Report) – Ever since Joe Biden first announced he would be running for president during the 2020 presidential election cycle, it has become clear that he is, how shall I put this, less than at his optimum level mentally speaking. We have witnessed the man take fall after fall, make gaffe after gaffe, wander around aimlessly while being guided by his wife and Secret Service agents, and on the list goes. Clearly, this man is not physically or mentally fit to discharge the duties of the office of president. That much seems apparent.

Many Americans have also recognized Biden’s cognitive decline, including individuals in the Democratic Party who didn’t want him to run for reelection, believing all of this, along with his poor economic policies and numerous scandals, would ultimately result in the GOP nominee taking the White House next year.

However, it looks like the Biden 2024 campaign has received some good news that might just assuage the fears of loyalist Democrat voters.

According to Andrew Stiles of The Washington Free Beacon, the Food and Drug Administration just gave full approval to a brand new Alzheimer’s treatment on July 6, which is less than three months after Biden announced he would be seeking a second term in the White House. How convenient, right?

The medication, known as Leqembi, is the first new Alzheimer’s treatment to receive full approval by the FDA in two decades, as well as being the first medication that slows the progression of the illness. You don’t need an IQ like Albert Einstein’s to read between the lines and see why this particular drug might have been pushed through the approval system with lightning speed.

“The FDA granted ‘accelerated approval’ for Leqembi in January 2023, roughly three months after Biden attempted to converse with a dead congresswoman at a White House nutrition conference. The FDA is a federal agency housed within the Department of Health and Human Services, which is run by a presidential appointee. The timing of the drug’s approval raises some troubling questions about government collusion and election interference,” Stiles wrote.

One of the reasons the approval of Leqembi matters so much is due to the fact that, Biden, who is 80-years-old and likely suffers from some form of cognitive decline, simply needs to be able to sit up and be moderately competent until after Election Day on Nov. 5, 2024. Once that occurs, should he win reelection, the left could utilize the 25th Amendment in order to justify forcing him to step down, allowing Vice President Kamala Harris to take his place.

“In phase 3 clinical trials, patients taking Leqembi experienced a 27 percent slower rate of decline compared with the placebo group. Side effects include brain swelling, seizures, and death,” Stiles continued. “Biden reportedly has been prone to violent temper tantrums since taking office, which is a common symptom of Alzheimer’s and other forms of cognitive decline. Biden’s cognitive decline was likely exacerbated by his failure to properly treat his longstanding sleep apnea, the Washington Free Beacon reported in June.”

The truth of the matter is, despite how one personally feels about Joe Biden, he’s an elderly man who is experiencing some sort of mental decline and should be resting at home with his family, not attempting to run a reelection campaign for the White House.

Copyright 2023. CongressReport.com

3 COMMENTS

  1. obiden definately needs that drug but with his America destroying performance his first 4 years….he WILL NOT get a chance to totally destroy us

  2. He needs to get his old college days job back, selling light bulbs to the blind.
    HE never did see the “LIGHT”!!!

LEAVE A REPLY

Please enter your comment!
Please enter your name here